Fatty Liver, Hepatitis, and Cirrhosis: What Most Patients in India Miss Until It's Too Late

Three of the most common liver conditions in India share one dangerous trait: they rarely cause symptoms early enough to prompt a visit to a doctor. By the time something feels wrong, the disease has often already progressed.

Liver disease in India is rising fastest in exactly the population that doesn't think it's at risk: working-age adults with no history of alcohol use, no family history of liver problems, and no obvious symptoms. Fatty liver (MASLD), viral hepatitis, and cirrhosis are clinically distinct conditions, but they share a pattern — silent progression, late presentation, and a diagnosis that often arrives only after the liver has already sustained damage.

This isn't a scare piece. It's a map of where the actual gaps in patient understanding sit, written from what comes up repeatedly in clinical practice.

Fatty Liver (MASLD): More Common, and More Misunderstood, Than People Think

Metabolic dysfunction–associated steatotic liver disease — MASLD, the term that has replaced "NAFLD" — is now estimated to affect roughly two in five adults in India. A 2026 community-based study from the Phenome India cohort, covering nearly 7,800 adults across 27 cities, found an age-adjusted MASLD prevalence of 38.9%, with measurable liver fibrosis already present in 2.4% of the overall population — concentrated in people over 60 and those with diabetes or higher-grade obesity.

The misconception that causes the most damage: "fatty liver" sounds harmless, almost cosmetic. It isn't. MASLD exists on a spectrum — simple fat accumulation, then inflammation (MASH), then fibrosis, and in a meaningful subset of patients, cirrhosis. The disease is usually asymptomatic at every stage except the last, which is precisely why population-level screening data consistently outpaces clinical diagnosis rates: most people with fibrosis don't know they have it.

What actually predicts risk in the Indian population: central obesity (which can be present even at a "normal" BMI), type 2 diabetes, insulin resistance, and dyslipidemia. South Asians are well documented to develop metabolic complications at lower BMI thresholds than Western populations, which means a patient who looks objectively fit can still be at meaningful risk.

What's actionable: fibrosis caught at an early stage, combined with weight reduction, glycemic control, and lipid management, can meaningfully improve or reverse liver injury. Fibrosis caught late cannot be reversed — only managed. The diagnostic tools that matter here are liver enzyme panels, FibroScan (transient elastography), and in selected cases, biopsy — not symptoms, because by the time MASLD causes symptoms, it has usually moved past the stage where lifestyle correction alone is sufficient.

Viral Hepatitis: India's Underdiagnosed Burden

Hepatitis B and C together account for the large majority of chronic liver disease and liver cancer cases linked to viral causes in India, and both diseases share the same structural problem: most infected people don't know they're infected.

India sits in the WHO's intermediate hepatitis B endemicity band, with general population HBV prevalence estimated at 2–4%, translating to roughly 40 million chronic carriers — among the largest HBV-infected populations of any country globally. Hepatitis C prevalence is lower nationally (national surveillance data places it around 0.3%, with urban areas more affected), but India remains among the small group of countries that together account for the majority of the world's hepatitis-related deaths, according to WHO's most recent global hepatitis reporting.

Why this matters clinically: chronic hepatitis B and C progress over years to decades with minimal or no symptoms. Fatigue, mild appetite changes, or nothing at all — until decompensated cirrhosis or hepatocellular carcinoma brings the patient in. I've seen patients with hepatitis infections dating back decades, never previously tested, presenting for the first time with advanced cirrhosis.

What changes the outcome: a single blood test (HBsAg for hepatitis B, anti-HCV antibody for hepatitis C). Hepatitis C is now curable in the large majority of patients with a finite course of direct-acting antivirals — typically 8 to 12 weeks. Hepatitis B isn't curable with current treatment, but it is highly controllable with antiviral therapy that prevents progression to cirrhosis and significantly reduces liver cancer risk. Neither benefit applies to a patient who was never tested.

Cirrhosis: A Diagnosis, not a Verdict

Cirrhosis is the point at which the liver's structure has been replaced, in part, by scar tissue — and it's frequently misunderstood by patients as an automatic countdown to transplant or death. That's not accurate.

What actually determines prognosis: whether the cirrhosis is compensated (the liver is scarred but still functioning adequately, often with few or no symptoms) or decompensated (marked by complications — ascites, variceal bleeding, hepatic encephalopathy, jaundice). Compensated cirrhosis can remain clinically stable for years with the right monitoring and management. Decompensation is the inflection point that changes the conversation toward transplant evaluation — and even then, "evaluation" does not mean "imminent transplant." It means establishing where a patient sits on a structured monitoring pathway.

The biggest avoidable failure point: patients diagnosed with compensated cirrhosis who don't return for regular monitoring because they feel fine. MELD score trends, surveillance imaging for liver cancer (every six months is standard for cirrhotic patients), and endoscopic screening for varices are not optional add-ons — they're what allows decompensation to be caught and managed before it becomes an emergency admission.

A Simple Way to Think About All Three

When to See a Hepatologist, Not Just a General Physician

A hepatologist's role isn't only end-stage liver disease. The highest-value visits are often the earliest ones: a patient with diabetes and elevated liver enzymes, a patient with a family member who had hepatitis B, a patient whose routine ultrasound mentioned "fatty liver" in passing. Subspecialty input at this stage is what determines whether a condition gets managed proactively or discovered only once it's advanced.

A liver diagnosis — or even an ambiguous finding on a routine scan — is worth a structured evaluation, not a wait-and-see approach. Dr. Chetan Kalal provides in-person consultations in Mumbai and virtual consultations for patients across India and internationally.

Book a Consultation · Request a Second Opinion

Frequently Asked Questions

Can fatty liver (MASLD) be reversed? In its early stages — simple fat accumulation without significant fibrosis — yes, largely through weight reduction, glycemic control, and lipid management. Once significant fibrosis has developed, the damage is generally not reversible, though further progression can often be slowed or halted. This is why early detection matters more than treatment intensity later.

How common is fatty liver in India? A 2026 community-based study (Phenome India cohort, ~7,800 adults across 27 cities) found an age-adjusted MASLD prevalence of 38.9%, with measurable fibrosis already present in 2.4% of the general population — higher in people over 60 and those with diabetes or obesity.

Is hepatitis B or C curable? Hepatitis C is curable in the large majority of patients with a finite 8–12-week course of direct-acting antivirals. Hepatitis B is not curable with current treatment but is highly controllable with long-term antiviral therapy that substantially reduces the risk of cirrhosis and liver cancer.

Does a cirrhosis diagnosis mean I need a liver transplant? Not necessarily. Compensated cirrhosis — where the liver is scarred but still functioning adequately — can remain stable for years with proper monitoring. Transplant evaluation becomes relevant at decompensation (complications like ascites, variceal bleeding, or jaundice) or based on MELD score trajectory, not at the point of diagnosis alone.

Who should get tested for hepatitis B and C even without symptoms? Anyone with a family history of hepatitis or liver disease, anyone who has had blood transfusions or surgery before universal screening protocols were standard, healthcare workers, and really, anyone who has never been tested — given how often these infections are diagnosed only after decades of silent progression.

Medical disclaimer: This article is for general informational purposes and does not constitute individual medical advice. Liver disease presentation, risk factors, and management vary by individual. Please consult Dr. Chetan Kalal or another qualified hepatologist for evaluation specific to your situation.

References

• Phenome India cohort, MASLD and liver fibrosis burden — Lancet Regional Health – Southeast Asia, 2026. DOI: 10.1016/j.lansea.2026.100723
• Chronic Hepatitis B: Challenges and Successes in India — PMC8518333
• WHO Global Hepatitis Report 2026 — who.int, April 2026
• Fast-pacing India's fight against viral hepatitis — Indian Journal of Medical Research, 2025